Collaboration seeks to develop genomic cancer assays

By Melissa Fassbender contact

- Last updated on GMT

Precision medicine based on advanced genomic and oncological technology has been the Macrogen's goal since its inspection. (Image: iStock)
Precision medicine based on advanced genomic and oncological technology has been the Macrogen's goal since its inspection. (Image: iStock)

Related tags: Oncology

Silicon Biosys­tems Menarini and Macrogen announced they will form a partnership to provide clinical assays and new procedures for precision medicine in cancer.

The collaboration will combine Silicon Biosystems' DEPArray digital-sorting technology with Macrogen's high-throughput next generation sequencing capabilities in order to develop tests certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 by the Centers for Medicare & Medicaid Services (CMS) of the US.

The certification, which is applicable to all clinical lab-testing performed on humans, helps ensure accuracy, reliability, and timeliness of test results.

Silicon Biosystems demonstrated the benefits of its DEPArray digital sorting toward obtaining “100% pure tumor and stromal cells for genetic profiling of FFPE tumor samples​,” in the February 2016 edition of Scientific Reports, according to the company’s president and CEO Giuseppe Giorgini.

"Pure cells provide exact answers about all kinds of genomic variation and instability from the level of targeted cancer panels up to the whole genome level, making DEPArray sorting and sequencing an unparalleled tool for precision patient stratification,” ​he added. “Furthermore, through DEPArray sorting we can help rescue samples with a very low number of tumor cells, like FNAs and low-cellularity FFPE​.”

We believe that Macrogen, with its proven NGS expertise, is an ideal partner to make such benefits available to patients and pharmaceutical companies through combined services provided in a CLIA environment​."

According to Jeong-Sun Seo, M.D., Ph.D., chairman of Macrogen, precision medicine based on advanced genomic and oncological technology has been the company’s goal since its inspection.

“This collaboration between Macrogen and Silicon Biosystems Menarini for the development of tumor-cell specific cancer somatic variants analysis will bring the critical benefit of precision medicine to cancer patients in urgent need sooner than we expected​," he said.

Macrogen is currently running two systems of HiSeq X Ten, providing whole-genome sequencing services worldwide. Under the collaboration, the company may also provide technical support for the somatic variant analysis of cancer cells by using its NGS expertise, as well as its clinical research capabilities.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars